The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice
Open accessAbstract
Activation of Kupffer cells plays a central role in the pathogenesis of alcoholic liver disease. Because cannabinoid CB2 receptors (CB2) display potent anti-inflammatory properties, we investigated their role in the pathogenesis of alcoholic liver disease, focusing on the impact of CB2 on Kupffer cell polarization and the consequences on liver steatosis. Wild-type (WT) mice fed an alcohol diet showed an induction of hepatic classical (M1) and alternative (M2) markers. Cotreatment of alcohol-fed mice with the CB2 agonist, JWH-133, decreased hepatic M1 gene expression without affecting the M2 profile. In keeping with this, genetic ablation of CB2 enhanced hepatic induction of M1 gene signature and blunted the induction of M2 markers. CB2 also modulated alcohol-induced fatty liver, as shown by the reduction of hepatocyte steatosis in JWH-133-treated mice and its enhancement in CB2−/− animals. Studies in isolated Kupffer cells and cultured macrophages further demonstrated that CB2 inhibits M1 polarization and favors the transition to an M2 phenotype. In addition, conditioned-medium experiments showed that preventing M1 polarization in CB2-activated macrophages protects from lipid accumulation in hepatocytes. Heme oxygenase-1 (HO-1) mediated the anti-inflammatory effects of CB2 receptors. Indeed, alcohol-fed mice treated with JWH-133 showed increased hepatic expression of macrophage HO-1, as compared to vehicle-treated counterparts. In keeping with this, JWH-133 induced HO-1 expression in cultured macrophages, and the HO-1 inhibitor, zinc protoporphyrin, blunted the inhibitory effect of JWH-133 on lipopolysaccharide-induced nuclear factor-kappa B activation and M1 polarization. Altogether, these findings demonstrate that CB2 receptors display beneficial effects on alcohol-induced inflammation by regulating M1/M2 balance in Kupffer cells, thereby reducing hepatocyte steatosis via paracrine interactions between Kupffer cells and hepatocytes. These data identify CB2 agonists as potential therapeutic agents for the management of alcoholic liver disease. (Hepatology 2011;)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Alternative activation of macrophages: mechanism and functions
Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Arnold, L., Henry, A., Poron, F., Baba-Amer, Y., van Rooijen, N., Plonquet, A., Gherardi, R. K., & Chazaud, B. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070075 · Cited by 2,002
Insulin and insulin resistance:
Sowers, J. R., & Frohlich, E. D. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00128-7 · Cited by 1,518
Cytokines in Alcoholic and Nonalcoholic Steatohepatitis
Tilg, H., & Diehl, A. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432007 · Cited by 948
Lucey, M. R., Mathurin, P., & Morgan, T. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0805786 · Cited by 863
Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., & Chawla, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.003 · Cited by 847
Arginase-1–Expressing Macrophages Suppress Th2 Cytokine–Driven Inflammation and Fibrosis
Pesce, J. T., Ramalingam, T. R., Mentink-Kane, M. M., Wilson, M. S., El Kasmi, K. C., Smith, A. M., Thompson, R. W., Cheever, A. W., Murray, P. J., & Wynn, T. A. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000371 · Cited by 816
Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., & Seki, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.052 · Cited by 741
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 709
Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice
Yin, M., Wheeler, M. D., Kono, H., Bradford, B. U., Gallucci, R. M., Luster, M. I., & Thurman, R. G. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70354-9 · Cited by 701
Kang, K., Reilly, S. M., Karabacak, V., Gangl, M. R., Fitzgerald, K., Hatano, B., & Lee, C.-H. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.002 · Cited by 699
Adiponectin Promotes Macrophage Polarization toward an Anti-inflammatory Phenotype
Ohashi, K., Parker, J. L., Ouchi, N., Higuchi, A., Vita, J. A., Gokce, N., Pedersen, A. A., Kalthoff, C., Tullin, S., Sams, A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088708 · Cited by 646
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T., Zimmer, A., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 544
Self-citationCB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Teixeira-Clerc, F., Julien, B., Grenard, P., Van Nhieu, J. T., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., & Lotersztajn, S. (2006) · Nature Medicine · doi:10.1038/nm1421 · Cited by 528
Self-citationHuang, W., Metlakunta, A., Dedousis, N., Zhang, P., Sipula, I., Dube, J. J., Scott, D. K., & O'Doherty, R. M. (2010) · Diabetes · doi:10.2337/db09-0016 · Cited by 520
Signalling pathways in alcohol-induced liver inflammation
Mandrekar, P., & Szabo, G. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.007 · Cited by 498
Iimuro, Y., Gallucci, R. M., Luster, M. I., Kono, H., & Thurman, R. G. (1997) · Hepatology · doi:10.1002/hep.510260621 · Cited by 497
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
Steffens, S., Veillard, N. R., Arnaud, C., Pelli, G., Burger, F., Staub, C., Zimmer, A., Frossard, J.-L., & Mach, F. (2005) · Nature · doi:10.1038/nature03389 · Cited by 472
Self-citationAntifibrogenic role of the cannabinoid receptor CB2 in the liver
Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J. T., Li, L., Karsak, M., Zimmer, A., Mallat, A., & Lotersztajn, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.050 · Cited by 470
Self-citationStienstra, R., Saudale, F., Duval, C., Keshtkar, S., Groener, J. E. M., van Rooijen, N., Staels, B., Kersten, S., & Müller, M. (2010) · Hepatology · doi:10.1002/hep.23337 · Cited by 452
Naveau, S., Chollet-Martin, S., Dharancy, S., Mathurin, P., Jouet, P., Piquet, M.-A., Davion, T., Oberti, F., Broët, P., & Emilie, D. (2004) · Hepatology · doi:10.1002/hep.20206 · Cited by 446
Cabral, G. A., & Griffin-Thomas, L. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000957 · Cited by 408 · cited 2×
“In addition, in vitro studies have shown that CB2-receptor activation impairs several macrophage functions, such as oxidized low-density lipoprotein (oxLDL)-induced inflammatory response, oxidative stress, migration, and antigen processing.(22) In the liver, recent data indicate that CB2 receptors are induced after ac…”
BackgroundIn Vitro-Derived Alternatively Activated Macrophages Reduce Colonic Inflammation in Mice
Hunter, M. M., Wang, A., Parhar, K. S., Johnston, M. J. G., Van Rooijen, N., Beck, P. L., & McKay, D. M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.041 · Cited by 311
Jeong, W.-I., Osei-Hyiaman, D., Park, O., Liu, J., Bátkai, S., Mukhopadhyay, P., Horiguchi, N., Harvey-White, J., Marsicano, G., Lutz, B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.007 · Cited by 310
Exacerbation of Alcoholic Liver Injury by Enteral Endotoxin in Rats
Mathurin, P., Deng, Q.-G., Keshavarzian, A., Choudhary, S., Holmes, E. W., & Tsukamoto, H. (2000) · Hepatology · doi:10.1053/jhep.2000.19621 · Cited by 297
Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective
Milligan, G. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.6.1271 · Cited by 252
Karlmark, K. R., Zimmermann, H. W., Roderburg, C., Gassler, N., Wasmuth, H. E., Luedde, T., Trautwein, C., & Tacke, F. (2010) · Hepatology · doi:10.1002/hep.23894 · Cited by 249
Cannabinoid‐2 receptor mediates protection against hepatic ischemia/reperfusion injury
Batkai, S., Osei‐Hyiaman, D., Pan, H., El‐Assal, O., Rajesh, M., Mukhopadhyay, P., Hong, F., Harvey‐White, J., Jafri, A., Haskó, G., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7451com · Cited by 246
Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver
Gustot, T., Lemmers, A., Moreno, C., Nagy, N., Quertinmont, E., Nicaise, C., Franchimont, D., Louis, H., Devière, J., & Le Moine, O. (2006) · Hepatology · doi:10.1002/hep.21138 · Cited by 244
Choi, K. M., Kashyap, P. C., Dutta, N., Stoltz, G. J., Ordog, T., Shea Donohue, T., Bauer, A. J., Linden, D. R., Szurszewski, J. H., Gibbons, S. J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.014 · Cited by 233
Deveaux, V., Cadoudal, T., Ichigotani, Y., Teixeira-Clerc, F., Louvet, A., Manin, S., Nhieu, J. T.-V., Belot, M. P., Zimmer, A., Even, P., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005844 · Cited by 227
Self-citationAoyama, T., Inokuchi, S., Brenner, D. A., & Seki, E. (2010) · Hepatology · doi:10.1002/hep.23795 · Cited by 211
Macrophage TNF-α contributes to insulin resistance and hepatic steatosis in diet-induced obesity
De Taeye, B. M., Novitskaya, T., McGuinness, O. P., Gleaves, L., Medda, M., Covington, J. W., & Vaughan, D. E. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00194.2007 · Cited by 208
Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats
Muñoz-Luque, J., Ros, J., Fernández-Varo, G., Tugues, S., Morales-Ruiz, M., Alvarez, C. E., Friedman, S. L., Arroyo, V., & Jiménez, W. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131896 · Cited by 180
Koop, D. R., Klopfenstein, B., Iimuro, Y., & Thurman, R. G. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.944 · Cited by 167
Xu, J., Lai, K. K. Y., Verlinsky, A., Lugea, A., French, S. W., Cooper, M. P., Ji, C., & Tsukamoto, H. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.034 · Cited by 159
Kyokane, T., Norimizu, S., Taniai, H., Yamaguchi, T., Takeoka, S., Tsuchida, E., Naito, M., Nimura, Y., Ishimura, Y., & Suematsu, M. (2001) · Gastroenterology · doi:10.1053/gast.2001.23249 · Cited by 158
Mandal, P., Park, P., McMullen, M. R., Pratt, B. T., & Nagy, L. E. (2009) · Hepatology · doi:10.1002/hep.23427 · Cited by 150
Devey, L. R., Ferenbach, D. A., Mohr, E., Sangster, K., Bellamy, C. O. C., Hughes, J., & Wigmore, S. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.237 · Cited by 137
Beneficial Paracrine Effects of Cannabinoid Receptor 2 on Liver Injury and Regeneration†
Teixeira-Clerc, F., Belot, M., Manin, S., Deveaux, V., Cadoudal, T., Chobert, M.-N., Louvet, A., Zimmer, A., Tordjmann, T., Mallat, A., et al. (2010) · Hepatology · doi:10.1002/hep.23779 · Cited by 125
Self-citationColmenero, J., Bataller, R. A., Sancho‐Bru, P., Bellot, P., Miquel, R., Moreno, M., Jares, P., Bosch, J., Arroyo, V., Caballería, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.12.036 · Cited by 124
CB2 receptors as new therapeutic targets for liver diseases
Lotersztajn, S., Teixeira-Clerc, F., Julien, B., Deveaux, V., Ichigotani, Y., Manin, S., Nhieu, J. T. V., Karsak, M., Zimmer, A., & Mallat, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707511 · Cited by 114
Self-citationEndocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver
Mallat, A., & Lotersztajn, S. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00467.2007 · Cited by 113
Self-citationHeme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts
Li, L., Grenard, P., Nhieu, J. T. V., Julien, B., Mallat, A., Habib, A., & Lotersztajn, S. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00906-5 · Cited by 81
Self-citationCannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases
Mallat, A., Teixeira-Clerc, F., Deveaux, V., & Lotersztajn, S. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.403 · Cited by 62
Self-citationYao, P., Hao, L., Nüssler, N. C., Lehmann, A., Song, F., Zhao, J., Neuhaus, P., Liu, L., & Nussler, A. K. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00555.2007 · Cited by 61
CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis
Wasmuth, H. E., & Trautwein, C. (2007) · Hepatology · doi:10.1002/hep.21527 · Cited by 33
Li, L., Julien, B., Grenard, P., Teixeira-Clerc, F., Mallat, A., & Lotersztajn, S. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.05.016 · Cited by 26
Self-citation
Cited by
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
Alcoholic liver disease: mechanisms of injury and targeted treatment
Louvet, A., & Mathurin, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.35 · Cited by 855
Self-citationEndocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
Self-citationDixon, L. J., Barnes, M., Tang, H., Pritchard, M. T., & Nagy, L. E. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120026 · Cited by 628
Macrophage Polarization and Its Role in Liver Disease
Wang, C., Ma, C., Gong, L., Guo, Y., Fu, K., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803037 · Cited by 581
Metadata
- Authors
- Louvet, A., Teixeira-Clerc, F., Chobert, M.-N., Deveaux, V., Pavoine, C., Zimmer, A., Pecker, F., Mallat, A., & Lotersztajn, S.
- Venue
- Hepatology
- Published
- 2011-10
- Volume
- 54
- Issue
- 4
- Pages
- 1217-1226
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2135530906
- Cited by
- 261
- References
- 52
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.